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A B S T R A C T
Excessive sitting is detrimentally associated with cardiovascular disease and all-cause mortality. Frequent breaks
in prolonged sitting can improve cardiometabolic responses in non-stroke populations. However, this has not
been established in stroke survivors. This study will determine the most effective dose of activity breaks that (i)
produce clinically meaningful improvements in mean systolic blood pressure (primary outcome), postprandial
glucose, and insulin responses (secondary outcomes), and (ii) is safe and feasible. We hypothesis that systolic
blood pressure, postprandial insulin, and glucose responses will improve with increasing doses of activity and be
most effective at the maximum safe and feasible dose of activity. Thirty participants in the most effective dose
will provide 80% power to detect a within-person, between-condition, difference of 3.5 mmHg in systolic blood
pressure assuming a SD of 15 mmHg, within-person correlation of 0.9, and α = 0.05. Stroke survivors will
complete 3 experimental conditions in a within-participant, dose escalation design including (i) uninterrupted
sitting (8 h), (ii) Dose 1: uninterrupted sitting with bouts of light-intensity exercises while standing (initial dose
involves two 5-min breaks), and (iii) Dose 2: two additional 5-min breaks above Dose 1. Ambulatory blood
pressure will be collected every 30 min during experimental conditions and hourly for 24-h post-experimental
conditions. Blood samples will be collected every 30 min during 2-h postprandial periods. This study will identify
the most effective dose of light-intensity exercises while standing to improve cardiometabolic responses in stroke
survivors.
1. Introduction and rationale
Prolonged sitting is associated with adverse health effects including
an increased risk of cardiovascular disease (CVD), all-cause mortality,
and diabetes [1,2]. Stroke survivors are a high-risk population that
spend 75% of their waking hours sitting and 52% in prolonged bouts of
sitting (≥30 min) [3], thus placing them at greater risk of further
cardiovascular events. Hypertension is the leading modifiable risk
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factor associated with first stroke and recurrent stroke [4,5]. Inter-
rupting prolonged sitting with frequent bouts of physical activity (e.g.
standing activities or walking) in non-stroke populations significantly
reduces blood pressure (BP) [6], postprandial glucose and insulin
concentrations [7,8]. In stroke survivors, our previous trial found that
breaking up prolonged sitting with frequent, short breaks of light-in-
tensity exercises while standing (STAND-EX) significantly reduced
systolic blood pressure (SBP) by an average of 3.5 mmHg [9]. This
improvement in SBP following frequent bouts of STAND-EX might
present a promising target to reduce recurrent stroke risk amongst
stroke survivors. While demonstrating proof of concept, the schedule of
activity breaks (3 min every 30 min) is not clinically applicable in
every-day life. Therefore, this new study builds on our previous BUST-
Stroke trial [9,10] and aims to investigate the dose-response of STAND-
EX bouts to reduce recurrent stroke risk and improve cardiometabolic
health in stroke survivors.
The aims of this study are to determine the most effective dose of
activity breaks that (i) produce clinically meaningful improvements in
mean SBP (primary outcome), postprandial glucose, and insulin re-
sponses (secondary outcomes), and (ii) is safe and feasible.
2. Methods
2.1. Design
Community dwelling stroke survivors will be recruited to this la-
boratory based, dose-escalation study. Each participant will complete a
familiarisation session followed by an uninterrupted sitting condition
and two dose-escalation conditions (Fig. 1). Ethics was obtained and
approved by the Hunter New England Human Research Ethics Com-
mittee (17/06/21/4.04) and registered with the University of New-
castle's Human Research Committee (H-2017-0296). The trial is regis-
tered with the Australian and New Zealand Clinical Trials Registry
(ACTRN12617001517369).
2.2. Patient population
Stroke survivors with a moderate walking disability will be re-
cruited to each cohort (n= 10/cohort).
Inclusion criteria: Stroke survivors > 3 months post-stroke;
Functional Ambulation Classification (FAC) ≥ 3 (able to ambulate on
level surfaces with or without supervision); walking speed ≥ 0.4 m/s;
able to stand from sitting with minimal assistance (≤1 person);
sit ≥ 7 h during waking hours; aged ≥ 18 years.
Exclusion criteria: Regularly engage in physical activity (≥150 min/
week); Body Mass Index (BMI) > 45 kg/m2; smoker; pregnant; clini-
cally diagnosed with an illness or condition that limits their ability to
complete each condition; urinary frequency or urgency; diabetes or
taking diabetic medication other than metformin.
2.3. Recruitment strategies
Participants will be recruited from the Hunter Stroke Research
Volunteer Register, through advertisement, social media posts and
presentations. Each participant will enrol in only one cohort.
2.4. Intervention
2.4.1. Familiarisation session
Baseline characteristics, including stroke profile (National Institutes
of Health Stroke Scale [11], Oxfordshire classification [12] and the
Fatigue Assessment Scale [13]), walking ability (10 m walk test, FAC),
Australian diabetes risk (AUSDRISK assessment tool [14]) and BP will
be measured. Dietary intake will be recalled (24-h recall) under gui-
dance of a dietitian. Participants will be fitted with a thigh-worn
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Fig. 1. Study schematic.
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activity monitor (activPAL3; PAL Technologies Ltd) and ambulatory
blood pressure monitor (ABPM 7100; Welch Allyn, Inc.) and instructed
in the pre-experimental day dietary and activity restrictions.
2.4.2. Pre-experimental day protocol
To reduce dietary-induced variations in glucose and insulin, dietary
intake will be standardised 24 h prior to, and during, each experimental
condition based on the procedures employed in our previous trial
[9,10]. Participants will follow a dietitian prescribed meal plan and be
provided with a standardised pre-experimental day evening meal and
asked to abstain from alcohol, caffeine and moderate-to-vigorous phy-
sical activity for 48 h before the experimental conditions.
2.4.3. Physical activity and ambulatory blood pressure monitoring
Physical activity and sedentary time will be recorded using an
activPAL3 for a minimum of 3 days prior to, and following, each ex-
perimental day. Ambulatory blood pressure (ABP) monitoring will
continue for 24 h after each experimental day, with hourly ABP re-
cordings. Participants will be asked to remain still whilst ABP mea-
surements are taken. All monitors will be positioned on the participant's
non-paretic limb.
2.4.4. Experimental day protocol
The protocol is adapted from a previous study completed in stroke
survivors (BUST-Stroke) [15]. Participants will arrive at 07:30 on each
experimental day and have their health status (presence of cold/flu-like
symptoms) and adherence to pre-experimental day protocols de-
termined. An intra-venous cannula will be inserted and fasting blood
samples will be collected (08:00am and 08:30am). Blood samples will
then be collected every 30 min during each 2 h postprandial period. BP
(measured with ABPM) will also be measured every 30 min, with re-
searchers and participants blinded to recordings. BP and blood samples
will be taken before bouts of STAND-EX. A standardised breakfast and
lunch meal will be provided at approximately 08:30am and 12:30pm,
respectively. Participants will be required to consume standardised
meals within 30 min. Heart rate, perceived exertion (using the BORG
0–10 scale) and time on task will be measured before and immediately
after each bout of STAND-EX, which will vary according to dose
escalation (Table 1). Fatigue will be assessed periodically throughout
the experimental day using a visual analogue scale. Water will be
consumed ad libitum during the baseline condition, with total intake
recorded and kept consistent between experimental conditions. Toilet
breaks will be noted and timed. Table 2 summarises the testing day
procedures.
The three experimental conditions will consist of:
1. Uninterrupted sitting – 8 h of prolonged, uninterrupted sitting in a
comfortable lounge chair (excluding toilet breaks).
2. Dose escalation 1 – Complete the prescribed dose of STAND-EX (calf-
raises, mini-squats and marching on the spot; BORG ≤ 3).
3. Dose escalation 2 – Complete an additional 10 min of STAND-EX
above Dose escalation 1.
Each 5-min bout of STAND-EX will be completed in the following
order and repeated 5 times: 20 s calf-raises, 20 s small amplitude squats,
and 20 s marching on the spot. Table 1 describes the schedule of
STAND-EX for each dose.
2.4.5. Dose-escalation
Escalation of STAND-EX will be completed in 10 min increments (2
x 5-min activity breaks). If a dose-limiting threshold (DLT) is not met,
the next cohort will commence dose escalation at the final dose com-
pleted by the previous cohort. Once DLT is met, a final cohort will re-
peat the dose escalation of the penultimate cohort to confirm this is the
maximum tolerable dose. Table 3 summarises dose escalation proce-
dures.
2.4.6. Dose-limiting threshold
The DLT is failure to achieve at least 80% of the target time in
STAND-EX due to fatigue, pain or effort. The maximum dose for a co-
hort will be considered reached if 70% or more of the cohort have met
the DLT.
2.4.7. Blood sampling and analysis
Blood samples will be collected in a 4 mL EDTA tube at each sam-
pling time-point (Table 2) to measure plasma glucose and insulin
Table 1
Break protocol for light-intensity exercises while standing.
Table 2
Testing day procedure.
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concentrations. Samples will be immediately refrigerated, centrifuged
within 60 min of collection, aliquoted and stored in a −80 °C freezer for
later analysis. Enzyme-linked immunosorbent assay (ELISA) will be
used to measure plasma insulin concentrations. Plasma glucose con-
centrations will be measured using the point of care i-STAT handheld
blood analysis device (i-STAT, Abbot Point of Care Inc.).
2.5. Study outcomes
The primary outcome is mean SBP (within-participant, between
condition differences) during and 24-h post experimental days.
Secondary outcomes are within-participant, between-condition differ-
ences for plasma glucose and insulin. Safety will be measured by the
number of adverse events, e.g. pain and discomfort from activity
breaks. Feasibility assessments will include measures of protocol ad-
herence and completion of activity breaks.
2.6. Sample size estimates
At study end, we will have data from n = 30 participants at the
maximum tolerable dose of STAND-EX. With an assumed SD of
15 mmHg (based on previous exercise trials in stroke survivors) and a
within-person correlation of 0.9, we will have 80% power to detect a
within-person, between condition difference of 3.5 mmHg in SBP
(α = 0.05).
2.7. Statistical analysis
SBP, blood glucose and insulin concentrations will be assessed using
generalised linear mixed models with random intercepts to account for
repeated measures on participants. On achieving the DLT, mean SBP,
blood glucose and insulin will be compared with baseline to identify
between condition differences. Safety and feasibility outcomes will be
evaluated descriptively, and by comparing odds of adverse events
across experimental conditions.
2.8. Study organisation and funding
This study is supported by a Hunter Medical Research Institute
project grant (2016) and Heart Foundation Vanguard Grant (2017 -
#101727). PhD Candidate Paul Mackie is supported by a University of
Newcastle PhD scholarship, A/Prof English is supported by a Heart
Foundation Future Leader Fellowship (#101177).
3. Discussion
As an extension to previous research [15], this trial will aim to
ascertain the dose of light-intensity exercises most effective to improve
mean SBP of stroke survivors that might reduce the risk of recurrent
stroke. Results from this trial will inform future studies aiming to re-
duce the recurrent risk of stroke in stroke survivors.
4. Conclusion
This dose escalation trial will further develop our understanding of
frequently interrupting prolonged sitting as a strategy to reduce blood
pressure and recurrent stroke risk.
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